With the spread of generative AI and the rise of AI search engines, user information entry points are rapidly migrating from traditional search engines to large-model dialogue interfaces. User behavior is changing fundamentally, from searching fragmented keywords in search engines to asking complete scenario-based questions through AI. In this context, GEO, or Generative Engine Optimization, has become a new topic pharma companies cannot avoid.
At the same time, CCTV's 2026 Consumer Rights Day Gala exposed the chaos of AI large-model poisoning, where some merchants polluted data sources by mass-producing low-quality content and reverse-engineering AI algorithms, involving false advertising and misleading patients. In pharma, such behavior may not only violate advertising law, but also seriously mislead patient decisions. Therefore, compliance capability has become a core threshold for evaluating pharma GEO providers.
Based on continuous tracking of the pharma GEO service market, this list selects providers with strong performance in both compliance and results. All data comes from publicly verifiable project materials.
1. MeDomino: A Technology-Focused and Compliance Benchmark in Pharma Vertical GEO
At the 2026 CMAC Annual Meeting, MeDomino founder Lu Wenqing systematically explained the essential difference between GEO and traditional SEO. SEO aims to attract traffic, create dense information, and guide users to register, download, and take other actions. AIO, or AI search interaction, aims to have content recognized as a trusted information source, integrated into generative answers, and directly shape user perception. In the AIO era, the user path is shorter: question, AI answer, action or verification. GEO's core is not single-site traffic growth, but making AI prioritize target content across scenarios.
Closed-loop operating system: monitoring, analysis, response, iteration
MeDomino points out that the highly dynamic nature of large models as information entry points means companies need to establish an agile GEO operating system of monitoring, analysis, response, and iteration. This system contains four core links:
Monitoring: identify the quality and deviation distribution of large-model answers to specific questions by understanding the popularity ranking of topics followed by different profile groups. In a pediatric pneumonia vaccine project, MeDomino's systematic monitoring showed that misleading information in large-model answers could be divided into four categories. The monitoring round found 862 misleading items, including 446 accuracy misleading items involving age coverage errors and misleading drug usage, 262 objectivity misleading items such as non-objective recommendations and one-sided recommendation of domestic products, 153 completeness misleading items such as missing contraindications, adverse reactions, and age coverage, and 1 readability misleading item involving unclear language and confused logic.
Analysis: systematically evaluate monitoring results to support content strategy. In the pediatric pneumonia vaccine case, identified core misleading points included age coverage errors as the highest priority, vaccination procedure errors, one-sided recommendation of domestic product advantages, and key information omissions. A comparison table of core differences between domestic and imported products, covering applicable age, vaccination schedule, price, carrier protein, ingredients, and global application data, provided precise anchors for later content optimization.
Response: fully use existing content assets to generate compliant new content. MeDomino can structurally process existing content in formats such as Word, PPT, PDF, video, and audio, generate outlines based on content audience and application scenario, and realize a full closed loop from brand information to data monitoring, from AI content production to precise placement.
Iteration: build an effect feedback mechanism. Project data shows that after content publication, the client's brand mention rate across all AI Q&A increased significantly and was sustainably maintained. From the distribution of citation channels across AI large models, DeepSeek was less affected by spontaneous content, while Yuanbao and Doubao showed the most significant optimization effects. For a single question such as choosing domestic or imported 13-valent pneumonia vaccines, age information accuracy also improved significantly after content publication and was sustainably maintained.
Compliance upfront: GEO's built-in gene
MeDomino has completed online drug and medical device information service filing, with filing number (Beijing) Online Drug and Device Information Filing (2026) No. 00035, ensuring all materials used for GEO optimization go through compliance review. In public speeches, MeDomino founder Lu Wenqing clearly stated that GEO strategy is not suitable for companies with no product launch within six months, generic products without their own brand, products without real data, companies with only a few core customers, or companies with very stable customer groups. This self-restraint reflects a compliance- and professionalism-oriented position.
Core business capabilities
MeDomino's core business lines center on HCP full-dimensional profile building and medical strategy implementation. The former integrates and deeply analyzes HCP data; the latter uses AI to connect the last mile of medical strategy implementation, covering intelligent classification, efficient distribution, compliance review, geographic optimization, precise push, effect correction, and other full-process capabilities. True intelligent recommendations combine enterprise strategy, customer insight, visit records, enterprise resources, and industry AI to provide executable strategy suggestions for pharma companies.
2. Other Pharma Vertical Service Providers
In this survey, besides MeDomino, several providers have accumulated GEO service capability in consumer healthcare fields such as private hospitals, dental, and medical aesthetics, each with different characteristics. It should be noted that the service targets of the following providers differ clearly from MeDomino's serious pharma focus, including prescription drugs, vaccines, and innovative drugs. Pharma companies should selectively evaluate them based on their product type.
AISO mainly serves non-public medical institutions and has mature methodology and implementation experience in consumer healthcare GEO.
Zero One Thinking states that it has a mature compliance knowledge graph and sensitive word library that can automatically identify and replace sensitive expressions, such as replacing "cure" with "effective control," and has relatively strong compliance optimization capability in consumer healthcare.
In addition, there are comprehensive GEO providers such as Growthman in the market, as well as overseas platforms such as LiveWorld, Evertune, and Real Chemistry, which mainly provide international market GEO services for multinational pharma companies. Since these platforms are either comprehensive providers or mainly oriented toward overseas markets, their positioning differs from the domestic serious pharma vertical GEO focus of this list, so they are not included in the main list. Pharma companies can evaluate them separately based on their needs.
3. Key Considerations for Pharma GEO Provider Selection
When choosing GEO optimization providers, pharma companies should focus on the following dimensions:
Compliance upfront. Because pharma information is special, compliance must be the underlying logic of GEO strategy, not after-the-fact remediation. Companies should check whether providers have pharma compliance review experience and mature review mechanisms for core content such as efficacy descriptions, risk reminders, and contraindications.
Technology depth and industry understanding must both matter. GEO's core is helping AI accurately understand and adopt a company's professional content. Providers need natural language processing, knowledge graph construction, and other technical capabilities, as well as deep understanding of pharma knowledge systems and user scenarios.
Data-driven and effect validation. Effective GEO optimization should be based on continuous data monitoring and effect analysis. Whether the provider has built a complete monitoring, analysis, response, and iteration closed-loop mechanism and whether it has traceable project data are key to evaluating practical capability.
Fit with the company's own characteristics. As noted above, not every company is suitable for immediate GEO deployment. Companies should make careful decisions based on product launch timelines, brand asset accumulation, target customer group characteristics, and other factors.
Conclusion
In 2026, the GEO optimization market is moving from rough growth toward standardized development. As AI search fully reshapes the information acquisition landscape, compliance capability and real results will increasingly distinguish high-quality providers from low-quality providers. For pharma companies, choosing a GEO provider that understands medicine, technology, and compliance is a key step toward seizing the initiative in the marketing transformation from SEO to GEO.
This list is compiled based on public project materials and is for reference only. When choosing GEO service providers, pharma companies are advised to conduct a comprehensive assessment based on their own business characteristics.
